| 摘要: |
| 目的探讨自体DC/CIK细胞免疫治疗对表皮生长因子受体（EGFR）基因突变阴性的晚期肺腺癌患者外周血微转移指标的影响。方法选择EGFR基因突变阴性的晚期肺腺癌患者120例，按随机数字表法分为治疗组和对照组各60例。治疗组进行DC/CIK细胞免疫治疗，对照组仅进行定期随访。采用RT-PCR法检测两组治疗前、治疗1个月和治疗3个月的外周血微转移指标（CEAmRNA、MKmRNA和LunxmRNA），同时观察两组患者的肿瘤无进展生存时间（PFS）。结果治疗组治疗1个月和3个月后3种指标的表达量均明显低于对照组，差异均有统计学意义（均P＜0.05）。同时两组在治疗1个月和3个月后3种指标的表达量均较治疗前明显上升，差异均有统计学意义（均P＜0.05）。此外，治疗3个月后，对照组有38例患者CEAmRNA达到了108copies/ml以上，有32例患者MKmRNA达到了109copies/ml以上，有35例患者LunxmRNA达到了109copies/ml。治疗组和对照组肿瘤的中位PFS分别是3.10和2.52个月，差异有统计学意义（P＜0.05）。结论自体DC/CIK细胞免疫治疗在EGFR基因突变阴性的晚期肺腺癌患者的维持治疗中达到了初步的疗效，一定程度上延长了生存时间。 |
| 关键词: 肺腺癌 DC/CIK 微转移指标 癌胚抗原 mRNA 中期因子 mRNA 肺癌特异性 X 蛋白 mRNA 维持治疗 |
| DOI：10.12056/j.issn.1006-2785.2017.39.7.2016-2188 |
| 分类号: |
| 基金项目:浙江省医药卫生平台计划（2015DTA016） |
|
| DC/CIK immunotherapy for patients with advanced lung cancer with negative EGFR gene mutation |
|
LU Huadong, MA Zhihong, LIU Zhicong, QIU Guoqin, HUA Feng, CUI Enhai, WANG Bin
|
|
Huzhou Central Hospital
|
| Abstract: |
| Objective To evaluate the clinical effect of DC/CIK immunotherapy in treatment of advanced lung adeno- carcinoma patients with negative epidermal growth factor receptor (EGFR) gene mutation. Methods One hundred and twenty advanced lung cancer patients with negative EGFR gene mutation were randomly divided into two groups with 60 cases in each group. Patients in treatment group received DC/CIK immunotherapy and those in control group were followed up only. Real-time PCR was used to examine the expression of CEA mRNA, MK mRNA and Lunx mRNA. Progression free survival (PFS) was used to monitor the change of clinical state after treatment with DC/CIK. And the results were analyzed statistically. Results The
expression levels of CEA mRNA, MK mRNA and Lunx mRNA in treatment group were lower than those in control group 1 and 3 months after treatment (all P＜0.05). After 3 months, in control group there were 38 cases with CEA mRNA ＞108 copies/ml, 32 cases with MK mRNA ＞109 copies/ml and 35 cases with Lunx mRNA＞109 copies/ml. In treatment group there was significant difference in CEA mRNA and MK mRNA expression before and after DC/CIK treatment(all P＜0.05). The progression-free survival in treatment and control groups was 3.10 months and 2.52 months, respectively (P＜0.05). Conclusion DC/CIK immunotherapy
can improve the quality of life and may be used as a maintenance treatment for patients with advanced lung adenocarcinoma. |
| Key words: Lung adenocarcinoma Dendritic cells- cytokine-induced killer cells Micrometastases Carcinoembryonic antigen mRNA Midkine mRNA Lung specific X protein mRNA Maintenance therapy |
